 Jody Tanabe
Concepts (323)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 61 | 2025 | 3566 | 3.540 |
Why?
| | Substance-Related Disorders | 18 | 2019 | 1083 | 3.240 |
Why?
| | Brain | 38 | 2025 | 2668 | 2.690 |
Why?
| | Brain Mapping | 23 | 2024 | 503 | 2.160 |
Why?
| | Nerve Net | 8 | 2019 | 256 | 1.670 |
Why?
| | Cerebrovascular Circulation | 8 | 2022 | 243 | 1.650 |
Why?
| | Cerebral Cortex | 15 | 2019 | 433 | 1.610 |
Why?
| | Prefrontal Cortex | 6 | 2017 | 301 | 1.410 |
Why?
| | Image Processing, Computer-Assisted | 22 | 2019 | 752 | 1.330 |
Why?
| | Decision Making | 9 | 2017 | 900 | 1.320 |
Why?
| | Acetates | 2 | 2021 | 99 | 1.290 |
Why?
| | Impulsive Behavior | 7 | 2015 | 150 | 1.210 |
Why?
| | Neuroimaging | 7 | 2025 | 259 | 1.180 |
Why?
| | Frontal Lobe | 7 | 2015 | 149 | 1.150 |
Why?
| | Gambling | 5 | 2015 | 33 | 1.030 |
Why?
| | Thalamus | 4 | 2021 | 107 | 0.950 |
Why?
| | Nicotine | 6 | 2013 | 334 | 0.920 |
Why?
| | Limbic System | 4 | 2015 | 47 | 0.910 |
Why?
| | Alzheimer Disease | 5 | 2025 | 560 | 0.870 |
Why?
| | Frontotemporal Dementia | 1 | 2024 | 57 | 0.860 |
Why?
| | Behavior | 3 | 2021 | 90 | 0.840 |
Why?
| | Risk-Taking | 3 | 2015 | 348 | 0.830 |
Why?
| | Psychotic Disorders | 2 | 2024 | 170 | 0.790 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2019 | 179 | 0.760 |
Why?
| | Nicotinic Agonists | 5 | 2011 | 129 | 0.760 |
Why?
| | Learning | 2 | 2019 | 409 | 0.740 |
Why?
| | Functional Neuroimaging | 2 | 2019 | 55 | 0.720 |
Why?
| | Sex Characteristics | 4 | 2020 | 762 | 0.710 |
Why?
| | Neostriatum | 2 | 2014 | 33 | 0.690 |
Why?
| | Pursuit, Smooth | 4 | 2005 | 19 | 0.690 |
Why?
| | Neuropsychiatry | 1 | 2020 | 17 | 0.690 |
Why?
| | Reward | 3 | 2023 | 244 | 0.680 |
Why?
| | Psychomotor Performance | 5 | 2017 | 309 | 0.660 |
Why?
| | Neural Pathways | 6 | 2017 | 295 | 0.660 |
Why?
| | Alcoholism | 4 | 2021 | 807 | 0.630 |
Why?
| | Software | 1 | 2024 | 665 | 0.620 |
Why?
| | Craving | 1 | 2019 | 39 | 0.610 |
Why?
| | Central Nervous System Depressants | 1 | 2019 | 85 | 0.610 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2019 | 60 | 0.610 |
Why?
| | Schizophrenia | 7 | 2023 | 439 | 0.590 |
Why?
| | Drug Users | 2 | 2016 | 40 | 0.580 |
Why?
| | Gray Matter | 2 | 2015 | 80 | 0.560 |
Why?
| | Male | 64 | 2025 | 67762 | 0.560 |
Why?
| | Adult | 47 | 2025 | 37929 | 0.550 |
Why?
| | Antiparkinson Agents | 1 | 2017 | 27 | 0.540 |
Why?
| | Levodopa | 1 | 2017 | 30 | 0.530 |
Why?
| | Humans | 84 | 2025 | 137585 | 0.530 |
Why?
| | Female | 63 | 2025 | 73304 | 0.530 |
Why?
| | Sensation Disorders | 1 | 2017 | 37 | 0.530 |
Why?
| | Tobacco Use Disorder | 1 | 2019 | 251 | 0.520 |
Why?
| | Parkinson Disease | 3 | 2017 | 493 | 0.510 |
Why?
| | Neuropsychological Tests | 9 | 2016 | 1023 | 0.510 |
Why?
| | Sexism | 1 | 2017 | 61 | 0.500 |
Why?
| | Ventral Striatum | 1 | 2015 | 8 | 0.460 |
Why?
| | Functional Laterality | 3 | 2013 | 223 | 0.460 |
Why?
| | Ethanol | 1 | 2019 | 608 | 0.450 |
Why?
| | Attention | 4 | 2005 | 427 | 0.440 |
Why?
| | Gyrus Cinguli | 5 | 2012 | 86 | 0.410 |
Why?
| | Cognition | 2 | 2019 | 1153 | 0.410 |
Why?
| | Magnetic Resonance Angiography | 2 | 2009 | 240 | 0.400 |
Why?
| | Cytokines | 1 | 2021 | 2085 | 0.400 |
Why?
| | Patient Selection | 1 | 2017 | 696 | 0.400 |
Why?
| | Deep Brain Stimulation | 2 | 2025 | 153 | 0.400 |
Why?
| | Amphetamine-Related Disorders | 3 | 2025 | 40 | 0.390 |
Why?
| | Conduct Disorder | 4 | 2017 | 201 | 0.390 |
Why?
| | Hippocampus | 7 | 2015 | 895 | 0.380 |
Why?
| | Healthcare Disparities | 1 | 2017 | 654 | 0.330 |
Why?
| | Inflammation | 1 | 2021 | 2837 | 0.320 |
Why?
| | Veins | 1 | 2009 | 63 | 0.310 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 4 | 2015 | 243 | 0.310 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2008 | 17 | 0.300 |
Why?
| | Middle Aged | 21 | 2025 | 33479 | 0.300 |
Why?
| | Spinal Cord Diseases | 1 | 2008 | 42 | 0.290 |
Why?
| | Atrophy | 6 | 2024 | 184 | 0.290 |
Why?
| | Reaction Time | 3 | 2013 | 412 | 0.280 |
Why?
| | Executive Function | 1 | 2013 | 451 | 0.280 |
Why?
| | Cues | 4 | 2019 | 314 | 0.280 |
Why?
| | Analysis of Variance | 4 | 2013 | 1316 | 0.270 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 14 | 0.250 |
Why?
| | Dementia, Vascular | 3 | 2000 | 20 | 0.240 |
Why?
| | Diffusion Magnetic Resonance Imaging | 3 | 2020 | 153 | 0.240 |
Why?
| | Intralaminar Thalamic Nuclei | 1 | 2025 | 16 | 0.240 |
Why?
| | Neuroradiography | 1 | 2024 | 5 | 0.230 |
Why?
| | High-Intensity Focused Ultrasound Ablation | 1 | 2025 | 9 | 0.230 |
Why?
| | Pilot Projects | 2 | 2021 | 1710 | 0.230 |
Why?
| | Evoked Potentials | 1 | 2005 | 123 | 0.220 |
Why?
| | Methamphetamine | 1 | 2025 | 63 | 0.220 |
Why?
| | Amyloid | 1 | 2025 | 87 | 0.220 |
Why?
| | Drug Resistant Epilepsy | 1 | 2025 | 102 | 0.210 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2003 | 21 | 0.210 |
Why?
| | Delay Discounting | 1 | 2023 | 23 | 0.210 |
Why?
| | Comprehension | 1 | 2025 | 172 | 0.210 |
Why?
| | White Matter | 1 | 2025 | 145 | 0.210 |
Why?
| | Central Nervous System Stimulants | 1 | 2025 | 161 | 0.200 |
Why?
| | Reference Values | 6 | 2021 | 816 | 0.200 |
Why?
| | Interview, Psychological | 2 | 2013 | 96 | 0.200 |
Why?
| | Ossification of Posterior Longitudinal Ligament | 1 | 2002 | 2 | 0.200 |
Why?
| | Perioperative Care | 1 | 2025 | 178 | 0.200 |
Why?
| | Young Adult | 8 | 2025 | 13209 | 0.200 |
Why?
| | Case-Control Studies | 5 | 2016 | 3556 | 0.200 |
Why?
| | Herpesvirus 1, Human | 1 | 2003 | 87 | 0.200 |
Why?
| | Thoracic Vertebrae | 1 | 2002 | 77 | 0.190 |
Why?
| | Adolescent Development | 2 | 2021 | 86 | 0.190 |
Why?
| | Marijuana Abuse | 1 | 2025 | 233 | 0.190 |
Why?
| | Multimodal Imaging | 2 | 2019 | 113 | 0.180 |
Why?
| | Administration, Oral | 2 | 2019 | 816 | 0.180 |
Why?
| | Alcohol Abstinence | 1 | 2021 | 12 | 0.180 |
Why?
| | Feedback, Psychological | 2 | 2013 | 20 | 0.180 |
Why?
| | Marijuana Use | 1 | 2025 | 206 | 0.180 |
Why?
| | Artificial Intelligence | 1 | 2024 | 279 | 0.170 |
Why?
| | Dementia | 1 | 2024 | 259 | 0.170 |
Why?
| | Photic Stimulation | 8 | 2017 | 241 | 0.170 |
Why?
| | Random Allocation | 1 | 2021 | 353 | 0.170 |
Why?
| | Benzylidene Compounds | 2 | 2010 | 20 | 0.170 |
Why?
| | Fingers | 2 | 2013 | 88 | 0.160 |
Why?
| | Oxygen | 4 | 2017 | 931 | 0.160 |
Why?
| | Immunotherapy | 1 | 2025 | 641 | 0.160 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1587 | 0.160 |
Why?
| | Aged | 13 | 2024 | 23961 | 0.160 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3284 | 0.160 |
Why?
| | Epilepsy | 1 | 2024 | 333 | 0.160 |
Why?
| | Cocaine-Related Disorders | 2 | 2012 | 113 | 0.160 |
Why?
| | Vasculitis, Central Nervous System | 1 | 2019 | 14 | 0.160 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2015 | 547 | 0.160 |
Why?
| | Tremor | 2 | 2017 | 65 | 0.160 |
Why?
| | Cerebellum | 3 | 2013 | 224 | 0.150 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7635 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2019 | 155 | 0.150 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 1998 | 89 | 0.140 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 294 | 0.140 |
Why?
| | Smoking | 3 | 2012 | 1627 | 0.140 |
Why?
| | Selection Bias | 1 | 2017 | 37 | 0.130 |
Why?
| | Cross-Over Studies | 4 | 2013 | 564 | 0.130 |
Why?
| | Artifacts | 3 | 2009 | 129 | 0.130 |
Why?
| | Pyridines | 2 | 2010 | 506 | 0.130 |
Why?
| | Spinal Cord | 1 | 1998 | 370 | 0.120 |
Why?
| | DiGeorge Syndrome | 1 | 2016 | 32 | 0.120 |
Why?
| | Surveys and Questionnaires | 4 | 2025 | 5778 | 0.120 |
Why?
| | Organ Size | 3 | 2015 | 477 | 0.120 |
Why?
| | Mental Disorders | 1 | 2023 | 1077 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 2 | 2009 | 580 | 0.110 |
Why?
| | Evoked Potentials, Visual | 3 | 2002 | 35 | 0.110 |
Why?
| | Brain Neoplasms | 1 | 2024 | 1238 | 0.110 |
Why?
| | Photoreceptor Cells | 2 | 1985 | 17 | 0.110 |
Why?
| | Postural Balance | 1 | 2017 | 215 | 0.110 |
Why?
| | Problem Behavior | 1 | 2015 | 102 | 0.110 |
Why?
| | Single-Blind Method | 2 | 2012 | 282 | 0.110 |
Why?
| | Brain Ischemia | 4 | 2000 | 338 | 0.100 |
Why?
| | Nucleus Accumbens | 1 | 2015 | 138 | 0.100 |
Why?
| | Adolescent | 11 | 2025 | 21513 | 0.100 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2013 | 36 | 0.100 |
Why?
| | Age Factors | 1 | 2021 | 3295 | 0.100 |
Why?
| | Longitudinal Studies | 2 | 2021 | 2844 | 0.100 |
Why?
| | Personality Inventory | 1 | 2013 | 139 | 0.100 |
Why?
| | Heroin Dependence | 1 | 2012 | 33 | 0.100 |
Why?
| | Alcohol Drinking | 1 | 2019 | 828 | 0.100 |
Why?
| | Principal Component Analysis | 1 | 2013 | 195 | 0.100 |
Why?
| | Cognition Disorders | 2 | 2010 | 496 | 0.090 |
Why?
| | Efficiency | 1 | 2012 | 99 | 0.090 |
Why?
| | Emotions | 1 | 2017 | 548 | 0.090 |
Why?
| | Adolescent Behavior | 1 | 2017 | 530 | 0.090 |
Why?
| | Susac Syndrome | 1 | 2011 | 3 | 0.090 |
Why?
| | Appetite Regulation | 1 | 2011 | 31 | 0.090 |
Why?
| | Fatal Outcome | 2 | 2019 | 303 | 0.090 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 77 | 0.080 |
Why?
| | Regression Analysis | 1 | 2013 | 1024 | 0.080 |
Why?
| | Research Design | 1 | 2017 | 1139 | 0.080 |
Why?
| | Comorbidity | 1 | 2015 | 1622 | 0.080 |
Why?
| | Cerebrospinal Fluid | 2 | 2003 | 92 | 0.080 |
Why?
| | Inpatients | 1 | 2014 | 500 | 0.080 |
Why?
| | Sex Factors | 1 | 2015 | 2071 | 0.080 |
Why?
| | Visual Perception | 1 | 2011 | 160 | 0.080 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1289 | 0.080 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2008 | 8 | 0.080 |
Why?
| | Temperance | 1 | 2008 | 13 | 0.080 |
Why?
| | Disease Progression | 2 | 2008 | 2757 | 0.070 |
Why?
| | Nutritional Status | 1 | 2011 | 350 | 0.070 |
Why?
| | Energy Intake | 1 | 2011 | 485 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2000 | 611 | 0.070 |
Why?
| | Receptors, Nicotinic | 1 | 2010 | 334 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 3 | 2024 | 2691 | 0.070 |
Why?
| | Wechsler Scales | 1 | 2007 | 54 | 0.070 |
Why?
| | Alcohols | 1 | 2007 | 27 | 0.070 |
Why?
| | Eye Movements | 2 | 2010 | 67 | 0.070 |
Why?
| | Chewing Gum | 1 | 2007 | 9 | 0.070 |
Why?
| | Exploratory Behavior | 1 | 2007 | 92 | 0.070 |
Why?
| | Event-Related Potentials, P300 | 2 | 2004 | 14 | 0.070 |
Why?
| | Alcohol-Related Disorders | 1 | 2008 | 122 | 0.070 |
Why?
| | Parietal Lobe | 2 | 2005 | 58 | 0.070 |
Why?
| | Normal Distribution | 1 | 2006 | 21 | 0.070 |
Why?
| | Electroencephalography | 3 | 2003 | 423 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2003 | 1483 | 0.060 |
Why?
| | Rod Cell Outer Segment | 1 | 1985 | 3 | 0.060 |
Why?
| | Color Vision Defects | 1 | 1985 | 8 | 0.060 |
Why?
| | Models, Neurological | 1 | 2007 | 242 | 0.060 |
Why?
| | Dissociative Disorders | 1 | 2005 | 22 | 0.060 |
Why?
| | Spinal Nerve Roots | 1 | 2005 | 29 | 0.060 |
Why?
| | Cranial Nerve Diseases | 1 | 2005 | 42 | 0.060 |
Why?
| | Taste | 1 | 2007 | 229 | 0.060 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2025 | 24 | 0.060 |
Why?
| | Essential Tremor | 1 | 2025 | 15 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2009 | 1993 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 2011 | 927 | 0.060 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2005 | 128 | 0.050 |
Why?
| | Aspartic Acid | 3 | 2000 | 79 | 0.050 |
Why?
| | Connectome | 1 | 2025 | 86 | 0.050 |
Why?
| | Ocular Motility Disorders | 1 | 2004 | 27 | 0.050 |
Why?
| | Aphasia | 1 | 2003 | 21 | 0.050 |
Why?
| | Personnel Selection | 1 | 2024 | 78 | 0.050 |
Why?
| | Child | 5 | 2024 | 21935 | 0.050 |
Why?
| | Surgery, Computer-Assisted | 1 | 2025 | 101 | 0.050 |
Why?
| | Psychopathology | 1 | 2023 | 56 | 0.050 |
Why?
| | Brain Diseases | 1 | 2024 | 141 | 0.050 |
Why?
| | Temporal Lobe | 1 | 2003 | 91 | 0.050 |
Why?
| | Heart Rate | 1 | 2007 | 822 | 0.050 |
Why?
| | United States | 3 | 2025 | 14841 | 0.050 |
Why?
| | Pattern Recognition, Visual | 1 | 2004 | 101 | 0.050 |
Why?
| | Echo-Planar Imaging | 1 | 2002 | 21 | 0.050 |
Why?
| | Acetazolamide | 1 | 2022 | 26 | 0.050 |
Why?
| | Mental Processes | 1 | 2002 | 32 | 0.050 |
Why?
| | Fourier Analysis | 1 | 2002 | 40 | 0.050 |
Why?
| | Nerve Fibers, Myelinated | 2 | 2005 | 47 | 0.050 |
Why?
| | Decompression, Surgical | 1 | 2002 | 106 | 0.050 |
Why?
| | Radiology | 1 | 2024 | 180 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2014 | 10811 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2024 | 512 | 0.050 |
Why?
| | Motor Activity | 1 | 2006 | 718 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2024 | 283 | 0.050 |
Why?
| | Stroke | 2 | 2019 | 1120 | 0.040 |
Why?
| | Memory, Short-Term | 1 | 2004 | 250 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2025 | 660 | 0.040 |
Why?
| | Language | 1 | 2024 | 292 | 0.040 |
Why?
| | Incidental Findings | 1 | 2021 | 87 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2003 | 1062 | 0.040 |
Why?
| | Liver Diseases | 1 | 2003 | 315 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 820 | 0.040 |
Why?
| | Seizures | 1 | 2003 | 426 | 0.040 |
Why?
| | Blood Pressure | 1 | 2007 | 1786 | 0.040 |
Why?
| | Multiple Sclerosis | 1 | 2005 | 455 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1946 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2019 | 36 | 0.040 |
Why?
| | Indocyanine Green | 1 | 2019 | 24 | 0.040 |
Why?
| | Cerebral Infarction | 1 | 1999 | 44 | 0.040 |
Why?
| | Algorithms | 1 | 2007 | 1704 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2025 | 804 | 0.040 |
Why?
| | Coloring Agents | 1 | 2019 | 87 | 0.040 |
Why?
| | Optical Imaging | 1 | 2019 | 64 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2019 | 145 | 0.040 |
Why?
| | Brain Chemistry | 1 | 1998 | 117 | 0.030 |
Why?
| | Obesity | 1 | 2011 | 2992 | 0.030 |
Why?
| | Kidney Failure, Chronic | 1 | 2003 | 570 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 413 | 0.030 |
Why?
| | Cannabis | 1 | 2025 | 494 | 0.030 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 213 | 0.030 |
Why?
| | Animals | 2 | 2019 | 36940 | 0.030 |
Why?
| | Cerebral Ventricles | 1 | 1997 | 52 | 0.030 |
Why?
| | Visual Acuity | 1 | 2019 | 356 | 0.030 |
Why?
| | Motor Neurons | 1 | 1998 | 234 | 0.030 |
Why?
| | Critical Illness | 1 | 2022 | 811 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2010 | 2057 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 786 | 0.030 |
Why?
| | Empathy | 1 | 2017 | 173 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 46 | 0.030 |
Why?
| | Age of Onset | 1 | 2016 | 518 | 0.030 |
Why?
| | Glucose | 1 | 1999 | 1020 | 0.030 |
Why?
| | Time Factors | 1 | 2024 | 6828 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5472 | 0.030 |
Why?
| | Hyperphagia | 1 | 2011 | 34 | 0.020 |
Why?
| | Sensation | 1 | 2011 | 53 | 0.020 |
Why?
| | Labor, Induced | 1 | 2011 | 33 | 0.020 |
Why?
| | Thinness | 1 | 2011 | 91 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 86 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5742 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2011 | 247 | 0.020 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 1 | 2010 | 97 | 0.020 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2011 | 132 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7604 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 176 | 0.020 |
Why?
| | Food | 1 | 2011 | 164 | 0.020 |
Why?
| | Fasting | 1 | 2011 | 281 | 0.020 |
Why?
| | Creatine | 2 | 2000 | 57 | 0.020 |
Why?
| | Hemodynamics | 1 | 2013 | 1113 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1066 | 0.020 |
Why?
| | Aspirin | 1 | 2011 | 387 | 0.020 |
Why?
| | Dominance, Cerebral | 1 | 2007 | 54 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2025 | 15657 | 0.020 |
Why?
| | Nerve Fibers | 1 | 2007 | 96 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 565 | 0.020 |
Why?
| | Cranial Nerves | 1 | 2005 | 12 | 0.010 |
Why?
| | Weight Loss | 1 | 2011 | 787 | 0.010 |
Why?
| | Sural Nerve | 1 | 2005 | 19 | 0.010 |
Why?
| | Graves Disease | 1 | 2005 | 34 | 0.010 |
Why?
| | Genotype | 1 | 2010 | 1916 | 0.010 |
Why?
| | Hypertrophy | 1 | 2005 | 133 | 0.010 |
Why?
| | Visual Pathways | 1 | 2005 | 55 | 0.010 |
Why?
| | Schizophrenic Psychology | 1 | 2005 | 94 | 0.010 |
Why?
| | Area Under Curve | 1 | 2005 | 314 | 0.010 |
Why?
| | Genetic Linkage | 1 | 2005 | 297 | 0.010 |
Why?
| | Treatment Failure | 1 | 2005 | 356 | 0.010 |
Why?
| | Genetic Markers | 1 | 2005 | 344 | 0.010 |
Why?
| | Early Diagnosis | 1 | 2005 | 242 | 0.010 |
Why?
| | Visual Fields | 1 | 2004 | 90 | 0.010 |
Why?
| | Gene Frequency | 1 | 2005 | 521 | 0.010 |
Why?
| | Axons | 1 | 2005 | 198 | 0.010 |
Why?
| | Myelin Sheath | 1 | 2005 | 167 | 0.010 |
Why?
| | Phenytoin | 1 | 1983 | 21 | 0.010 |
Why?
| | Head | 1 | 2004 | 105 | 0.010 |
Why?
| | Electrolytes | 1 | 1983 | 58 | 0.010 |
Why?
| | Neural Inhibition | 1 | 2004 | 169 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2189 | 0.010 |
Why?
| | Visual Cortex | 1 | 2002 | 70 | 0.010 |
Why?
| | Movement | 1 | 2004 | 278 | 0.010 |
Why?
| | Risk | 1 | 2004 | 912 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 890 | 0.010 |
Why?
| | Tomography, Emission-Computed | 1 | 1999 | 66 | 0.010 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 80 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 6763 | 0.010 |
Why?
| | Protons | 1 | 1997 | 89 | 0.010 |
Why?
| | Choline | 1 | 1998 | 127 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2004 | 2426 | 0.010 |
Why?
| | Biomarkers | 1 | 2005 | 4149 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 1999 | 2828 | 0.010 |
Why?
| | Dogs | 1 | 1983 | 413 | 0.000 |
Why?
|
|
Tanabe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|